Logo image of CYAD.BR

CELYAD ONCOLOGY (CYAD.BR) Stock Fundamental Analysis

Europe - Euronext Brussels - EBR:CYAD - BE0974260896 - Common Stock

0.182 EUR
0 (-1.09%)
Last: 12/24/2025, 7:00:00 PM
Fundamental Rating

1

CYAD gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 81 industry peers in the Biotechnology industry. CYAD has a bad profitability rating. Also its financial health evaluation is rather negative. CYAD is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CYAD has reported negative net income.
CYAD had a negative operating cash flow in the past year.
CYAD had negative earnings in each of the past 5 years.
In the past 5 years CYAD always reported negative operating cash flow.
CYAD.BR Yearly Net Income VS EBIT VS OCF VS FCFCYAD.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

Looking at the Return On Assets, with a value of -113.33%, CYAD is doing worse than 80.72% of the companies in the same industry.
Industry RankSector Rank
ROA -113.33%
ROE N/A
ROIC N/A
ROA(3y)-106.35%
ROA(5y)-75.65%
ROE(3y)-741.18%
ROE(5y)-467.96%
ROIC(3y)N/A
ROIC(5y)N/A
CYAD.BR Yearly ROA, ROE, ROICCYAD.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

1.3 Margins

Looking at the Gross Margin, with a value of 94.09%, CYAD belongs to the top of the industry, outperforming 90.36% of the companies in the same industry.
CYAD's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for CYAD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 94.09%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-1.32%
CYAD.BR Yearly Profit, Operating, Gross MarginsCYAD.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200K -400K -600K -800K

More info and screens

0

2. Health

2.1 Basic Checks

CYAD does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CYAD has about the same amount of shares outstanding.
CYAD has more shares outstanding than it did 5 years ago.
CYAD has a worse debt/assets ratio than last year.
CYAD.BR Yearly Shares OutstandingCYAD.BR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
CYAD.BR Yearly Total Debt VS Total AssetsCYAD.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -6.38, we must say that CYAD is in the distress zone and has some risk of bankruptcy.
CYAD's Altman-Z score of -6.38 is on the low side compared to the rest of the industry. CYAD is outperformed by 72.29% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -6.38
ROIC/WACCN/A
WACC7.05%
CYAD.BR Yearly LT Debt VS Equity VS FCFCYAD.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

A Current Ratio of 0.66 indicates that CYAD may have some problems paying its short term obligations.
CYAD has a worse Current ratio (0.66) than 79.52% of its industry peers.
A Quick Ratio of 0.59 indicates that CYAD may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.59, CYAD is doing worse than 81.93% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.66
Quick Ratio 0.59
CYAD.BR Yearly Current Assets VS Current LiabilitesCYAD.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

CYAD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 30.43%, which is quite impressive.
CYAD shows a strong growth in Revenue. In the last year, the Revenue has grown by 158.33%.
CYAD shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 98.73% yearly.
EPS 1Y (TTM)30.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28.57%
Revenue 1Y (TTM)158.33%
Revenue growth 3YN/A
Revenue growth 5Y98.73%
Sales Q2Q%0%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CYAD.BR Yearly Revenue VS EstimatesCYAD.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2023 2024 2M 4M 6M 8M
CYAD.BR Yearly EPS VS EstimatesCYAD.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CYAD. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CYAD.BR Price Earnings VS Forward Price EarningsCYAD.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CYAD.BR Per share dataCYAD.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.05 -0.1 -0.15 -0.2 -0.25

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

CYAD does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

CELYAD ONCOLOGY

EBR:CYAD (12/24/2025, 7:00:00 PM)

0.182

0 (-1.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)09-25 2025-09-25
Earnings (Next)N/A N/A
Inst Owners58.62%
Inst Owner ChangeN/A
Ins Owners0.45%
Ins Owner ChangeN/A
Market Cap4.11M
Revenue(TTM)186.00K
Net Income(TTM)-6.46M
Analysts42.22
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 22.11
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.16
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.27
FCFYN/A
OCF(TTM)-0.27
OCFYN/A
SpS0.01
BVpS-0.14
TBVpS-0.15
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -113.33%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 94.09%
FCFM N/A
ROA(3y)-106.35%
ROA(5y)-75.65%
ROE(3y)-741.18%
ROE(5y)-467.96%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-1.32%
F-Score3
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.66
Quick Ratio 0.59
Altman-Z -6.38
F-Score3
WACC7.05%
ROIC/WACCN/A
Cap/Depr(3y)50.48%
Cap/Depr(5y)38.94%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28.57%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)158.33%
Revenue growth 3YN/A
Revenue growth 5Y98.73%
Sales Q2Q%0%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y17.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y70%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y69.45%
OCF growth 3YN/A
OCF growth 5YN/A

CELYAD ONCOLOGY / CYAD.BR FAQ

What is the ChartMill fundamental rating of CELYAD ONCOLOGY (CYAD.BR) stock?

ChartMill assigns a fundamental rating of 1 / 10 to CYAD.BR.


What is the valuation status of CELYAD ONCOLOGY (CYAD.BR) stock?

ChartMill assigns a valuation rating of 0 / 10 to CELYAD ONCOLOGY (CYAD.BR). This can be considered as Overvalued.


What is the profitability of CYAD stock?

CELYAD ONCOLOGY (CYAD.BR) has a profitability rating of 1 / 10.


Can you provide the financial health for CYAD stock?

The financial health rating of CELYAD ONCOLOGY (CYAD.BR) is 0 / 10.